N/A N=40 Citicoline in Non-Arteritic Ischemic Optic Neuropathy
Non-arteritic Ischemic Optic Neuropathy
Primary: Change From Baseline in Visual Acuity at 9 Month — -0.0574; 0.0535 LogMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Non-arteritic Ischemic Optic Neuropathy · Optic Nerve Injuries
Primary: Mean Increase From Baseline in ETDRS Letters Read at 26 Weeks and Off-drug Follow-up Visit — 15; 7; 9; 6 EDTRS Letters
Phase 1 N=2 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart
N/A N=21,283 Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Anterior Ischemic Optic Neuropathy · Ischemic Optic Neuropathy
Primary: Crude Incidence Rate of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Per 1000 Person-years by Age — 0.01; 0.01; 0.03; 0.12 incidence rate per 1000 person-years
Phase 2 N=117 Traumatic Optic Neuropathy Treatment Trial (TONTT)
Traumatic Optic Neuropathy
Primary: Number of Participants With Change/Improvement Visual Acuity From the Beseline — 28; 3; 5 Participants
Phase 2 N=71 Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic Neuritis
Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron
Phase 2 N=70 Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients
N/A N=22 Trial of Alternating Current Stimulation in Optic Neuropathy
Optic Nerve Diseases · Optic Nerve Injuries · Optic Neuropathies
Primary: Detection Accuracy (DA) Change in Percent Over Baseline Within Defective Visual Field Sectors — 24.75; 39.16 percent change
N/A N=129 Optical Coherence Tomography Angiography Evaluation of Ocular Changes in Patients With Carotid Artery Stenosis
Carotid Stenosis
Primary: Radical Peripapillary Capillaries Vessel Density — 55.95; 57.24 percentage of vessel
Phase 3 N=44 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
Optic Neuritis
Primary: Retinal Nerve Fiber Layer Thickness at Baseline and Month 6 — 128.1; 130.5; 89.5; 88.0 µm
Phase 2 N=82 BIIB033 In Acute Optic Neuritis (AON)
Acute Optic Neuritis
Primary: Change in Full-field Visual Evoked Potential (FF-VEP) Latency at Week 24: Intent-to-treat (ITT) Population — 20.83; 17.34 msec — p=0.3337
Phase 3 N=46 Ampyra for Optic Neuritis in Multiple Sclerosis
Multiple Sclerosis · Optic Neuritis
Primary: Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores — -0.04; -0.06; -0.08; -0.06 LogMAR…
N/A N=345 A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: 30-Day Person Time Analysis Risk of NAION Associated With PDE5 Inhibitor Use — 2.27 Relative risk of exposure
Phase 2 N=22 Sildenafil for Treatment of Choroidal Ischemia
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
N/A N=673 A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Optic Neuropathy, Ischemic
Primary: Number of Days Exposed to PDE5i During 1-Day Case Window and 29 1-Day Control Windows Among Participants Adjudicated as Definite NAION Cases — 14; 248 exposed days…
N/A N=44 Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect
Multiple Sclerosis · Glaucoma
Primary: Number of Participants With Detected Relative Afferent Pupillary Defect (RAPD) — 44; 37 participants
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 4 N=30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
N/A N=16 Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients
Fabry Disease
Primary: Blood Oxygenation at the Optic Nerve Head — 60.8; 65.3 percentage of oxygen saturation
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
N/A N=100 Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion
Elevated Intracranial Pressure (ICP)
Primary: Changes in ONSD in mm With Changes in ICP in Healthy Volunteers. — 4.2 mm
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
N/A N=46 The Effects of an Antioxidant Formulation on Ocular Blood Flow
Primary Open Angle Glaucoma
Primary: Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) — -0.026; 0.011 % zero pixels — p=0.0016
N/A N=49 The Efficacy of Normobaric Oxygen on Chronic Cerebral Ischemia
Normobaric Oxygen · Cerebral Ischemia
Primary: The Fronto-central Theta Absolute Power Change Rate — 0.14; -0.12 ratio
N/A N=7 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
Neovascular Glaucoma
Primary: Incidence of Adverse Events — 3; 4 Participants